Board re-appoints MD and Whole-time Director for three years

Management Changes View source PDF Explain this filing

SENORES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.1%Reaction day

₹1321.90

prior close

₹1299.30

announcement price

In-mkt

timing

Nifty Microcap 250market+0.2%-0.3% vs market

Pharmaceuticals peers, median of 168sector-0.3%+0.3% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+0.0

15m

-0.2

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.1+0.2-0.3-0.3+0.3

Next day

-3.1+0.9-4.0-0.3-2.8

-4.8-0.8-4.1-1.2-3.7

-0.2-0.1-0.2-1.0+0.8

-4.9-1.7-3.2-2.6-2.3

-7.0-4.3-2.7-3.8-3.2

-8.2-7.5-0.7-6.4-1.7

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 168Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board re-appointed Mr. Swapnil Jatinbhai Shah as Managing Director for 3 years from Oct 15, 2026, and Mr. Chetan Bipinchandra Shah as Whole-time Director for 3 years from Nov 10, 2026. Both are existing directors; MD Swapnil Shah is also a promoter with 15+ years in pharma. Both re-appointments need shareholder approval via postal ballot.

Likely market impact

Continuity in leadership as promoter Swapnil Shah and COO Chetan Shah continue. Shareholder approval via postal ballot pending.